GSK 2793660

Drug Profile

GSK 2793660

Alternative Names: GSK-2793660

Latest Information Update: 20 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bronchiectasis

Most Recent Events

  • 19 Apr 2015 GlaxoSmithKline terminates phase I trial in Bronchiectasis (in volunteers) in United Kingdom (NCT02058407)
  • 01 Jan 2014 Phase-I clinical trials in Bronchiectasis (in volunteers) in United Kingdom (PO, capsule; PO, liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top